Axxcess Wealth Management LLC Sells 3,563 Shares of Cencora, Inc. (NYSE:COR)

Axxcess Wealth Management LLC lessened its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 34.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,826 shares of the company's stock after selling 3,563 shares during the period. Axxcess Wealth Management LLC's holdings in Cencora were worth $1,534,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of COR. Cozad Asset Management Inc. lifted its position in shares of Cencora by 64.1% in the fourth quarter. Cozad Asset Management Inc. now owns 3,815 shares of the company's stock worth $857,000 after buying an additional 1,490 shares during the last quarter. Counterpoint Mutual Funds LLC lifted its holdings in Cencora by 79.3% in the 4th quarter. Counterpoint Mutual Funds LLC now owns 6,136 shares of the company's stock worth $1,379,000 after purchasing an additional 2,713 shares during the last quarter. Signaturefd LLC boosted its position in Cencora by 8.4% during the fourth quarter. Signaturefd LLC now owns 3,614 shares of the company's stock worth $812,000 after purchasing an additional 279 shares during the period. Parallel Advisors LLC grew its holdings in Cencora by 6.4% during the fourth quarter. Parallel Advisors LLC now owns 5,265 shares of the company's stock valued at $1,183,000 after purchasing an additional 317 shares during the last quarter. Finally, Cibc World Markets Corp raised its position in shares of Cencora by 15.7% in the fourth quarter. Cibc World Markets Corp now owns 27,753 shares of the company's stock valued at $6,236,000 after purchasing an additional 3,764 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Remove Ads

Insider Activity at Cencora

In related news, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,970 shares of company stock valued at $2,998,670 over the last quarter. Corporate insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

COR has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Mizuho started coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target for the company. Finally, Wells Fargo & Company raised their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $280.20.

Cencora Price Performance

COR traded down $0.13 during trading on Monday, hitting $267.30. The company's stock had a trading volume of 1,056,808 shares, compared to its average volume of 1,377,904. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market capitalization of $51.83 billion, a price-to-earnings ratio of 38.02, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The firm's 50 day moving average price is $250.62 and its two-hundred day moving average price is $240.01. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $277.61.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.82%. Cencora's dividend payout ratio (DPR) is currently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.